Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 12, No 4 (2016) The use of oral anticoagulants in patients with atrial fibrillation: cohort study data Abstract  similar documents
O. V. Gaisenok, A. S. Leonov
"... . Results. The rate of OAC use was 46.5% (warfarin – 22.4%, NOAC – 20.7%), antiplatelet agents use – 60 ..."
 
Vol 10, No 6 (2014) THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER Abstract  similar documents
S. Y. Martsevich, A. R. Navasardyan, N. P. Kutishenko, A. V. Zakharova, V. P. Voronina, N. A. Dmitrieva, L. Yu. Lrozdova, A. V. Zagrebelnyy, O. V. Lerman, Yu. V. Lukina, G. V. Martynova, A. A. Nikulina, G. S. Ryazanova, A. Yu. Suvorov, S. N. Tolpygina
"... Aim. To study in the PROFILE register the rate of new oral anticoagulants (NOAC) taking ..."
 
Vol 13, No 2 (2017) ORAL ANTICOAGULANTS IN AMBULATORY AND IN-HOSPITAL TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION ASSOCIATED WITH HYPERTENSION, ISCHEMIC HEART DISEASE AND CHRONIC HEART FAILURE: DATA FROM HOSPITAL REGISTRY RECVASA-CLINIC Abstract  PDF (Eng)  similar documents
E. V. Stepina, M. M. Loukianov, M. A. Bichurina, E. N. Belova, E. V. Kudryashov, Ju. V. Uzkov, S. A. Boytsov
"... Aim. To estimate the rate of oral anticoagulants (OAC) prescription, continuity of anticoagulant ..."
 
Vol 15, No 4 (2019) The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries) Abstract  similar documents
M. M. Loukianov, S. Yu. Martsevich, O. M. Drapkina, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, E. M. Pozdnyakova, T. A. Gomova, E. E. Fedotova, M. N Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, E. Y. Andreenko, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, M. A. Panagopulu, S. A. Boytsov
"... Aim. To evaluate an incidence of oral anticoagulants (OAC) administration during longterm follow ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... . In connection with the known disadvantages of warfarin use, the elaboration of new oral anticoagulants (NOAC ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
"...   favorable profile of drug  interaction in comparison with other new oral anticoagulants (NOAC). The basis ..."
 
Vol 15, No 1 (2019) Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City Abstract  similar documents
A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich
"... . In addition, an assessment of the dynamics of the frequency of the OAC prescription during 2015-2017 ..."
 
Vol 14, No 4 (2018) Risk Controlling of Gastrointestinal Bleeding in Comorbid Patients with Cardiovascular Diseases Abstract  similar documents
O. Yu. Chizhova, L. N. Belousova, I. G. Bakulin
"... anticoagulants (NOACs), previously known as new oral anticoagulants are used in the treatment and prevention ..."
 
Vol 12, No 3 (2016) THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT Abstract  PDF (Eng)  similar documents
S. R. Gilyarevskiy
"... , as well as the choice of anticoagulants, including new oral anticoagulants (NOAC). EINSTEIN-PE is the only ..."
 
Vol 10, No 6 (2014) THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY Abstract  similar documents
A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
"... problems. New oral anticoagulants (NOAC) are promising drugs for use in oncology practice; however ..."
 
Vol 12, No 1 (2016) Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis Abstract  similar documents
V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov
"... Aim. Analysis of the efficacy and safety of the new oral anticoagulants (NOACs) in the management ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... oral anticoagulants (NOACs). Material and methods. Cost-effectiveness analysis was performed using ..."
 
Vol 14, No 6 (2018) Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice Abstract  PDF (Eng)  similar documents
K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova
"... + antiplatelet agent) and 1 (1.0%) case – a monotherapy. Among all cases of OAC prescription warfarin ..."
 
Vol 14, No 2 (2018) WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY Abstract  similar documents
R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin
"... warfarin, 15% new oral anticoagulants (NOAC). The majority of patients received antiplatelet agents ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
"... of various manifestations of liver damage in the use of the new oral anticoagulants (NOAC) for the registered ..."
 
Vol 12, No 5 (2016) Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms Abstract  PDF (Eng)  similar documents
Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev
"... .7%; Kolmogorov-Smirnov; p<0.05). Patients receiving new oral anticoagulants (NOAC) have better compliance ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... lately new oral anticoagulants (NOAC) are becoming more common for the prevention of thromboembolic ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... oral anticoagulants (NOAC) instead of vitamin K antagonists (eg, warfarin), low doses of NOAC, studied ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
"... oral anticoagulants (NOAC): 1) none of the randomized controlled trials (RCTs) with NOAC (except ..."
 
Vol 14, No 5 (2018) Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin
"... This article affects  the problems of using NOAC in the most defenseless groups  of patients ..."
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... oral anticoagulants (NOAC). However, the secondary stroke prevention in these pa- tients remains ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... антикоагулянты (НОАК) хотя и обла- дают клиническим преимуществом перед варфарином, однако их применение ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... антикоагулянтов [2-4]. У пациентов с неклапанной ФП новые пероральные антикоагулянты (НОАК: апик- сабан ..."
 
Vol 10, No 1 (2014) THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME Abstract  similar documents
A. N. Zakirova, E. Z. Fatkullina, N. E. Zakirova
"... .61 and 183.6±17.2 ng/ml in grade 3 obesity vs 3.5±0.3 and 291.7±22.4 ng/ml in grade 1 obesity; p<0 ..."
 
Vol 13, No 3 (2017) DRUG TREATMENT OF PATIENTS WITH THE HISTORY OF ACUTE STROKE: DATA OF THE PILOT PHASE OF THE OUTPATIENT REGISTRY «REGION» Abstract  similar documents
S. A. Boytsov, M. M. Loukianov, S. S. Yakushin, S. Yu. Martsevich, L. V. Stakhovskaya, A. N. Vorobyev, A. V. Zagrebelnyy, A. N. Kozminsky, K. A. Moseichuk, K. G. Pereverzeva, E. A. Pravkina, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, A. D. Deev
"... кровообращения любой давности 59% 45% 9% 15% 3% 5% 41% 23% OAC / ОАК OAC + ASA / ОАК + АСК Without ATT ..."
 
Vol 12, No 1 (2016) The main factors affecting the long-term outcomes in patients after acute cerebrovascular disorder: results of the LIS-2 study Abstract  similar documents
S. Yu. Martsevich, N. P. Kutishenko, A. V. Suvorov, A. V. Zagrebelnyy, M. L. Ginzburg, A. D. Deev
"... .5% of the patients died during this period. The main cause of death (36%) was re-MI, and 22.4% of patients died from ..."
 
Vol 4, No 4 (2008) PRIORITIES IN CONCEPT OF CARDIOVASCULAR RISK FACTORS IN IRRADIATED PATIENTS AT DISTANT PERIOD AFTER CHERNOBYL NUCLEAR DISASTER BASED ON PROSPECTIVE COHORT DATA Abstract  similar documents
R. G. Oganov, V. S. Sherashov, N. V. Sherashova, M. V. Sherashova, S. K. Kukushkin, O. G. Rudakova, E. A. Zhavoronkova
"... . 409 irradiated patients and 224 control patients comparable on the age and gender were involved ..."
 
Vol 8, No 4 (2012) COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART I) Abstract  similar documents
S. Y. Martsevich, S. N. Tolpygina
"... as a trend for HOMA index decrease. Serum creatinine level increased in patients of the group 2 (6.35±22.4 ..."
 
Vol 13, No 6 (2017) HEART RATE AND ITS ASSOCIATION WITH THE MAIN RISK FACTORS IN THE POPULATION OF MEN AND WOMEN OF WORKING AGE Abstract  similar documents
S. А. Shalnov, A. D. Deev, O. A. Belova, Yu. I. Grinshtein, D. V. Duplyakov, A. Yu. Efanov, E. V. Indukaeva, N. V. Kulakova, R. A. Libis, S. V. Nedogoda, O. P. Rotar, G. V. Tolparov, I. A. Trubacheva, T. M. Chernykh, A. A. Shabunova, S. A. Boytsov
"... elevated blood pressure (OR 2.24, 95% CI 1.88-2.67), elevated levels of triglycerides, glucose and CRP ..."
 
Vol 13, No 6 (2017) RISK FACTORS OF ARTERIAL HYPERTENSION IN ORGANIZED COHORT OF MALE EMPLOYEES OF THE MACHINE BUILDING PLANT Abstract  similar documents
A. N. Britov, S. A. Tjupaeva, N. A. Eliseeva, A. N. Meshkov, A. D. Deev
"... in 44.8% of hypertensive patients vs 22.4% in people without HT (p<0.001). The people with HT ..."
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... антикоагулянтов (НОАК), внимание специалистов здравоохранения приковано к эффективности и безопасности терапии. В ..."
 
Vol 11, No 1 (2015) ON THE SELECTION OF DRUGS DOSAGE REGIMEN Abstract  similar documents
E. N. Bochanova
"... пероральных анти- коагулянтов (НОАК; ривароксабан, дабигатран) все шире применяются в клинической практике ..."
 
Vol 13, No 1 (2017) ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY Abstract  similar documents
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... смертности [13]. Сравнительные исследования АСК с новыми перо- ральным антикоагулянтами (НОАК) более ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... ) Triple therapy (NOAC + A + K) Тройная терапия (ППОАК+А+К) Dual Therapy (NOAC + A or K) Двойная терапия ..."
 
Vol 6, No 5 (2010) THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY Abstract  similar documents
T. V. Kozlova, I. M. Makeyeva, V. Y. Doroshina, S. I. Bokareva
"... витамина К (ОАК-АВК) и нуждающихся в хи- рургической или иной инвазивной помощи, является определенной ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... - мость назначения антикоагулянтов, в частности, из группы новых пероральных антикоагулянтов (НОАК), у ..."
 
Vol 8, No 5 (2012) RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE Abstract  similar documents
I. V. Grajfer, L. E. Kuvshinova, P. V. Dolotovskaya, O. V. Reshet'ko, N. V. Furman
"... результатам различных исследований при- менение оральных антикоагулянтов (ОАК) имело пре- имущество перед ..."
 
Vol 10, No 6 (2014) PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION Abstract  similar documents
N. V. Mikheeva, O. V. Reshetko, N. V. Furman
"... перенесенного инфаркта мозга на фоне ФП реко- мендована терапия пероральными антикоагулянта- ми (ОАК) (I, А) [1 ..."
 
Vol 12, No 1 (2016) Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita Abstract  similar documents
S. N. Bel'diev
"... , в таб- лице «Лекарственные взаимодействия и выбор дозы но- вых пероральных антикоагулянтов (НОАК ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... years лет 224 Ration Pharmacother Cardiol 2016;12(2) / Рациональная Фармакотерапия в Кардиологии 2016 ..."
 
Vol 11, No 2 (2015) CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASES: FOCUS ON ATRIAL FIBRILLATION Abstract  similar documents
V. N. Shishkova
"... антикоагулянты Новые пероральные антикоагулянты (НОАК) имеют механизмы действия и свойства, отличающиеся от та ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... (НОАК), лишённых недостатков варфарина, воз- можности антикоагулянтной терапии при ФП значи- тельно ..."
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract  similar documents
article editorial
"... антикоагу- лянтов (НОАК) у пациентов с ФП и наличием тромбов в левом предсердии (ЛП) или ушке левого ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... сегодняшний день т.н. «новые» пероральные ан- тикоагулянты (НОАК) являются в ряде случаев реаль- ной ..."
 
Vol 13, No 2 (2017) ONCE AGAIN ABOUT THE HIERARCHY OF EVIDENCES IN MEDICINE OR WHETHER IT IS POSSIBLE TO CHOOSE THE MOST EFFECTIVE AND SAFE DRUG WITH THE HELP OF OBSERVATIONAL STUDIES Abstract  similar documents
S. Y. Martsevich, Yu. V. Lukina, N. P. Kutishenko
"... антикоагулянтов (НОАК), препаратов, относительно недавно появившихся на фармацевти- ческом рынке, предназначенных ..."
 
Vol 12, No 2 (2016) SYSTEMATIC REVIEW AND META-ANALYSIS: PITFALLS OF METHODS Abstract  similar documents
Yu. V. Lukina, S. Yu. Martsevich, N. P. Kutishenko
"... (НОАК) у больных с венозными тром- боэмболическими осложнениями (ВТЭО). Мета-ана- лиз был выполнен в ..."
 
Vol 12, No 1 (2016) The Moriscos-Green scale: the pros and cons of universal test, correction of mistakes Abstract  PDF (Eng)  similar documents
Yu. V. Lukina, S. Yu. Martsevich, N. P. Kutishenko
"... приверженности к приему новых ораль- ных антикоагулянтов (НОАК) у пациентов с фибрилляцией предсердий (ФП) по ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... ) / Рациональная Фармакотерапия в Кардиологии 2017;13(3) 417 Введение Группа новых оральных антикоагулянтов (НОАК ..."
 
Vol 13, No 1 (2017) EVALUATION OF TREATMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION BEFORE REFERENCE EVENT AND BEFORE DISCHARGE FROM THE HOSPITAL: REGISTER DATA (KHABAROVSK CITY). PART 2 Abstract  similar documents
L. N. Malay, S. Yu. Martsevich, L. V. Solokhina, Y. M. Bukhonkina, K. E. Poshatayev, N. B. Garayeva, A. Ya. Letskin
"... (4,98) Антиагреганты 92 (28,7) Статины 44 (13,7) Антикоагулянты (варфарин+НОАК; 41 пациент с ФП) 7 ..."
 
Vol 12, No 3 (2016) CORRELATIONS OF DIFFERENT STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF ARTERIAL WALL WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS IN HEALTHY PEOPLE OF DIFFERENT AGE. PART 2 Abstract  PDF (Eng)  similar documents
I. D. Strazhesko, O. N. Tkacheva, D. U. Akasheva, E. V. Dudinskaya, M. V. Agaltsov, A. S. Kruglikova, N. V. Brailova, V. S. Pykhtina, E. V. Plokhova, N. V. Sharashkina, O. Yu. Isaykina, V. A. Vygodin, S. A. Boytsov
"... .068 Fasting hyperglycemia, % / ГГН, % 22.4 10.4 33.3 <0.001 Type 2 diabetes, % / СД 2 типа, % 16.5 5.6 26.4 <0 ..."
 
Vol 5, No 3 (2009) CARDIOVASCULAR DISEASES TREATMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CURRENT CLINICAL PRACTICE Abstract  PDF (Eng)  similar documents
I. E. Sapozhnikova, E. I. Tarlovskaya, E. N. Anufrieva
"... (22.4) / 23 (13.8) 1 incorrectly choosed drug 6 (3.6) Irrational two-drug combination 31 (18.7) Low ..."
 
Vol 11, No 1 (2015) THE WAY OF ASSESSING THE ADHERENCE TO MODERN DRUG THERAPY CLINICAL GUIDELINES AIMED AT REDUCING THE RISK OF RECURRENT STROKE (ACCORDING TO THE LIS-2 REGISTER) Abstract  similar documents
A. Yu. Suvorov, S. Yu. Martsevich, N. P. Kutishenko, A. D. Deev, M. L. Ginzburg, A. V. Akimova, E. V. Daniels, N. A. Dmitrieva, L. Yu. Drozdova, N. Yu. Zhuravskaya, O. V. Lerman, Yu. V. Lukina, M. M. Loukianov, V. P. Smirnov, A. V. Fokina
"... достижение 1,5 балла за данное У пациентов с ФП/ТП при отсутствии МНО 2,0-3,0 в стационаре или ОАК, не ..."
 
Vol 10, No 5 (2014) NEWS FROM THE ANNUAL CONGRESS OF EUROPEAN SOCIETY OF CARDIOLOGY (BARCELONA 2014): REALIZED AND UNREALIZED EXPECTATIONS Abstract  similar documents
S. Y. Martsevich, N. P. Kutishenko
"... антикоагулянтами, 11,5% получают аспирин, 32,3% – варфарин, осталь- ные – новые пероральные антикоагулянты (НОАК ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... . Warfarin was prescribed in 73% of the pa- tients, novel oral anticoagulants were distributed as follows: 22.4 ..."
 
Vol 12, No 4 (2016) Comparative Analysis of All-cause and Cardiovascular Mortality in Moscow and Irkutsk Abstract  PDF (Eng)  similar documents
F. I. Belyalov, I. V. Samorodskaya, S. V. Pogodaeva
"... : 224 and 166 per 100,000 of population in the USA and United Kingdom, respectively. Accuracy ..."
 
Vol 13, No 1 (2017) THE STUDY "REGISTER OF PATIENTS AFTER ACUTE STROKE (REGION)". PART 2. OUTPATIENT PROSPECTIVE REGISTER OF PATIENTS AFTER ACUTE STROKE (ACCORDING TO THE RESULTS OF THE PILOT PHASE OF THE STUDY) Abstract  PDF (Eng)  similar documents
S. А. Boytsov, M. M. Loukianov, S. S. Yakushin, S. Yu. Martsevich, L. V. Stakhovskaya, A. N. Vorobyev, A. V. Zagrebelnyy, N. P. Kutishenko, A. N. Kozminsky, K. A. Moseichuk, K. G. Pereverzeva, E. A. Pravkina, E. N. Belova, E. V. Kudryashov, A. D. Deev
"... as follows: oral anticoagulants (OAC), cardiac glycosides, an- tioxidants and statins. The patients ..."
 
Vol 12, No 5 (2016) Lung Function Parameters in Patients with Dilated Cardiomyopathy Complicated by Pulmonary Hypertension Abstract  similar documents
T. A. Abdullaev, Ya. R. Ahmatov, B. U. Mardanov, R. Sh. Bekbulatova
"... значениях пико- вой скорости выдоха составила 22,4% (р<0,05 для обо- их; табл. 2). Следующим этапом нашего ..."
 
Vol 12, No 6 (2016) THE STUDY "REGISTER OF PATIENTS AFTER ACUTE STROKE (REGION)." Part 1. Hospital Prospective Register of Patients after Acute Stroke (According to the Results of the Pilot Phase of the Study) Abstract  similar documents
S. A. Boytsov, S. Yu. Martsevich, N. P. Kutishenko, M. M. Loukianov, A. E. Mitichkin, R. V. Viskov, L. V. Stakhovskaya, N. A. Shamalov, G. P. Arutyunov, I. V. Kokareva, N. E. Parsadanyan, M. I. Chernyshova, A. V. Zagrebelnyy, N. A. Dmitrieva, A. V. Akimova, G. I. Nikitina, O. V. Lerman, V. P. Voronina, E. N. Belova, E. N. Kudryashov, A. D. Deev
"... ,5 Антагонисты кальция 33 36,6 Диуретики 31 34,4 Статины 62 68,9 Варфарин и НОАК (ФП=20) 5+1 30,0 Антиагреганты ..."
 
Vol 5, No 5 (2009) IN THE ISSUE Abstract  similar documents
"... ,5 38,5±22,4*** 30,0±22,4 38,3±27,1* *-p<0,05; **-p<0,01; ***-p<0,001 — значимость различий по ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... еще не проводилось. В настоящее время в Японии проводит- ся исследование X-NOAC, в котором сравнивают ..."
 
Vol 10, No 2 (2014) PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN MIDDLE-AGED MALES (15-YEAR FOLLOW-UP): CLINICAL AND ECONOMIC ASPECTS OF THE PROBLEM Abstract  PDF (Eng)  similar documents
A. M. Kalinina, A. V. Kontsevaya
"... in the groups of active prevention and comparison, respectively), in- cidence of arterial hypertension (22.4 ..."
 
Vol 12, No 3 (2016) EFFECT OF GENDER DIFFERENCES ON THE EFFICACY AND SAFETY OF REPERFUSION THERAPY OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (DATA OF RETROSPECTIVE SINGLE-CENTER STUDY – HOSPITAL PERIOD) Abstract  PDF (Eng)  similar documents
D. B. Nemik, G. V. Matyushin, A. V. Protopopov, A. V. Shulmin, S. A. Ustyugov
"... 307 случаев ИМпST (224 мужчины и 83 женщины) в период 2011 по 2012 гг., и в группе контроля (n=523 ..."
 
Vol 13, No 3 (2017) SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION Abstract  similar documents
S. B. Fitilev, D. A. Dimitrova, I. I. Shkrebneva, A. V. Vozzhaev
"... ,2) Атеросклероз сосудов головного мозга, n (%) 69 (22,4) 119 (23,0) Инсульт, n (%) 15 (4,9) 47 (9,1)* Атеросклероз ..."
 
Vol 2, No 3 (2006) ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? Abstract  similar documents
I. A. Latfullin, A. A. Podolskaya
"... имеет их стоимость. В настоящее время из оральных антикоагулянтов (ОАК) наиболее широко применяется ..."
 
Vol 11, No 2 (2015) ВСЕРОССИЙСКАЯ НАУЧНО-ПРАКТИЧЕСКАЯ КОНФЕРЕНЦИЯ «НЕИНФЕКЦИОННЫЕ ЗАБОЛЕВАНИЯ И ЗДОРОВЬЕ НАСЕЛЕНИЯ РОССИИ» 28-29 МАЯ 2015, МОСКВА Abstract  similar documents
"... Российское кардиологическое общество Национальное общество доказательной фармакотерапии 224 Рациональная ..."
 
Vol 9, No 3 (2013) INFLUENCE OF ACARBOSE ON POSTPRANDIAL DYSMETABOLISM: RESULTS OF AN OPEN-LABEL RANDOMIZED STUDY Abstract  PDF (Eng)  similar documents
A. Ya. Cherniak, I. M. Petrov, I. V. Medvedeva
"... 224 Рациональная Фармакотерапия в Кардиологии 2013;9(3) Influence of acarbose on postprandial ..."
 
Vol 9, No 6 (2013) DYNAMICS IN MEDICAL TREATMENT OF ISCHEMIC HEART DISEASE IN CLINICAL PRACTICE Abstract  PDF (Eng)  similar documents
S. A. Shalnova, A. D. Deev, S. A. Boytsov
"... препарата No preparations / не принимали 22,4 33,8 27,3 10,1 6,4 Figure 1. Distribution of the number ..."
 
Vol 13, No 4 (2017) PATIENTS WITH ATRIAL FIBRILLATION IN MULTIDISCIPLINARY HOSPITAL: STRUCTURE OF HOSPITALIZATION, CONCOMITANT CARDIOVASCULAR DISEASES AND DRUG TREATMENT (DATA OF RECVASA AF-TULA REGISTRY) Abstract  similar documents
M. N. Valiakhmetov, T. A. Gomova, M. M. Loukianov, S. Yu. Martsevich, K. N. Nadejkina, M. N. Artemova, D. N. Jilin, E. E. Fedotova, A. V. Zagrebelnyy, E. V. Kudryashov, S. A. Boytsov
"... », «неврологическая» и «те- рапевтическая», в которые включены 493, 224 и 265 пациентов, соответственно (рис. 1 ..."
 
Vol 8, No 4 (2012) THE EFFECT OF COMBINED ANTIHYPERTENSIVE THERAPY ON THE BASIC PARAMETERS OF THE LEFT VENTRICLE MYOCARDIUM STRUCTURE AND FUNCTION IN WOMEN WITH METABOLIC SYNDROME AND HYPOTHYROIDISM Abstract  similar documents
V. V. Skibitskiy, A. V. Fendrikova, N. E. Pykhalova
"... выраженным уменьшением ТМЖП (-18,2% про- тив -13,6%), ММЛЖ (-27,5% против -22,4%) и ИММ ЛЖ (-24% против -18 ..."
 
Vol 4, No 5 (2008) CARDIOVASCULAR RISK IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE ROLE OF SYSTEMIC INFLAMMATION AND ENDOTHELIAL DYSFUNCTION Abstract  similar documents
D. A. Poddubnyy, A. P. Rebrov
"... анкилозирующим спондилитом (спонди- лоартритом - АК) достоверно превышает показатель у здоровых лиц (224 [112 ..."
 
Vol 9, No 4 (2013) EFFECT OF IRON AND SELENIUM DRUGS ON DIASTOLIC MYOCARDIAL FUNCTION IN PATIENTS WITH ANEMIC CARDIOMYOPATHY Abstract  similar documents
E. V. Goncharova, A. V. Govorin
"... ,25 1,34±0,23*** 1,99±0,48††† 2 Передняя базальный 2,20±0,16 1,19±0,28*** 2,11±0,74††† 8 медиальный 2,24 ..."
 
Vol 3, No 4 (2007) EFFECT OF BRONCHODILATORS ON HEART RATE VARIABILITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
H. H. Shugushev, M. V. Gurizeva, V. M. Vasilenko
"... средний, мс 871,1±22,4 655,1±17,0^ 686,2±13,7^ 642,2±12,0^ 691,8±9,7^ RR минимальный, мс 667,9±29,1 591 ..."
 
Vol 7, No 5 (2011) EFFECT OF ERYTHROPOIETIN ON THE CLINICAL COURSE OF CHRONIC HEART FAILURE IN PATIENTS WITH ANEMIA: RESULTS OF NOT COMPARATIVE STUDY Abstract  similar documents
V. M. Provotorov, S. A. Avdeeva
"... ; 4 (5):224-228. Russian (Арутюнов Г.П. Анемия у больных хронической сердечной недостаточностью ..."
 
Vol 5, No 5 (2009) EFFICACY AND SAFETY OF VASOACTIVE BETA-BLOCKERS IN ACUTE PHARMACOLOGICAL TEST IN HYPERTENSIVE PATIENTS OF DIFFERENT AGES Abstract  similar documents
O. V. Fedorishina, A. A. Dzizinsky, K. V. Protasov, V. A. Protasova, T. I. Kucherova, E. G. Zakharova, D. D. Baskhaeva, T. S. Sukhoroslova, O. V. Perkova
"... - 24, %а 27,5±19,5 38,5±22,4*** 30,0±22,4 38,3±27,1* *-p<0,05; **-p<0,01; ***-p<0,001 — значимость ..."
 
Vol 10, No 5 (2014) OUTPATIENT REGISTRY OF CARDIOVASCULAR DISEASES (RECVASA): PROSPECTIVE FOLLOW-UP DATA, ESTIMATION OF RISKS AND OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  PDF (Eng)  similar documents
M. M. Loukianov, S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, A. N. Vorobyev, A. V. Zagrebelnyy, M. S. Kharlap, K. G. Pereverzeva, E. A. Pravkina, S. E. Serdyuk, A. D. Deev, E. N. Kudryashov
"... .27 1.41 3.55 2.75 (p=0.0002*) 1.73 3.272.38 (p=0.0001*) 2.52 (p=0.0006*) 2.24 (p=0.0006*) 0 0,25 0 ..."
 
Vol 12, No 1 (2016) CONCOMITANT CARDIOVASCULAR DISEASES AND ANTIHYPERTENSIVE TREATMENT IN OUTPATIENT PRACTICE (BY THE RECVASA REGISTRY DATA) Abstract  PDF (Eng)  similar documents
M. M. Loukianov, S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, A. N. Vorobyev, A. V. Zagrebelnyy, N. N. Nikulina, K. G. Pereverzeva, E. A. Pravkina, A. D. Deev, E. V. Kudryashov, E. N. Belova
"... ) 54.3 22.4 76.7 39.8 MI + stroke / ИМ+МИ (n=72) 50.0 19.4 69.4 47.2 CHF + MI + stroke / ХСН+ИМ+МИ (n ..."
 
Vol 12, No 2 (2016) CORRELATIONS OF DIFFERENT STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF ARTERIAL WALL WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS IN HEALTHY PEOPLE OF DIFFERENT AGE. PART 1 Abstract  PDF (Eng)  PDF (Eng)  similar documents
I. D. Strazhesko, O. N. Tkacheva, D. U. Akasheva, E. V. Dudinskaya, M. V. Agaltsov, A. S. Kruglikova, N. V. Brailova, V. S. Pykhtina, E. V. Plokhova, N. V. Sharashkina, O. Yu. Isaykina, V. A. Vygodin, S. A. Boytsov
"... hyperglycemia / Гипергликемия натощак, % 22.4 10.4 33.3 <0.001 Type 2 diabetes mellitus / Сахарный диабет 2 типа ..."
 
Vol 8, No 4 (2012) ACETYLSALICYLIC ACID: WHAT'S NEW IN THE OLD DRUG? Abstract  similar documents
I. V. Zhirov
"... ,35–0,81) 0,003 Другое 224 0,89 (0,65–1,23) 0,48 0,79 (0,50–1,24) 0,30 Не определено 106 0,91 (0,58–1 ..."
 
Vol 8, No 2 (2012) ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS  similar documents
Lei Zhang, Yizhou Lu, Hong Jiang, Liming Zhang, Aijun Sun, Yunzeng Zou, Junbo Ge
"... ,30 [-0,83, 0,24] Gunes 2009 -22,4 51,37 51 -16,9 60,56 36 19,1% -0,10 [-0,53, 0,33] Sisakian 2007 -23 28 ..."
 
Vol 9, No 3 (2013) IMPACT OF LOCUS 9P21.3 SINGLE NUCLEOTIDE POLYMORPHISMS ON CORONARY ATHEROSCLEROSIS SEVERITY AND LONG-TERM OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENT WITH MYOCARDIAL INFARCTION Abstract  similar documents
P. A. Shesternya, G. V. Matyushin, S. Yu. Nikulina, A. S. Sergeeva
"... ,7) – двухсосудистое 84 (32,9) – трехсосудистое 57 (22,4) – отсутствие атеросклеротического поражения 18 (7 ..."
 
Vol 4, No 2 (2008) RAMIPRIL EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION AND ISCHEMIC HEART DISEASE Abstract  similar documents
A. I. Chesnikova, I. N. Koshenskaja, V. P. Terentyev, N. N. Mozhaeva, I. V. Bedareva, L. A. Lavrik, T. V. Zhertovsky
"... ПАД ночное 1-я группа 2-я группа * - p<0,05 -4.7 -22.4* -5.0 -20.1* -1.8 -22.3* Рамиприл у ..."
 
Vol 12, No 4 (2016) Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk Abstract  similar documents
O. M. Drapkina, O. N. Korneeva
"... women. How big is the influence of gender? Serdtse 2011; 10 (4): 224-8. In Russian (Драпкина О ..."
 
Vol 7, No 6 (2011) CURRENT APPROACHES TO EVALUATION OF THE MULTIVESSEL CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE Abstract  similar documents
D. N. Perutsky, I. B. Kovalenko, S. L. Konstantinov, T. I. Makeeva, M. V. Filatov
"... ; 360:213–224. 19. Wijns W., De Bruyne B., Vanhoenacker P.K. What does the clinical cardiologist need ..."
 
Vol 4, No 2 (2008) ACUTE CORONARY SYNDROME IN PATIENTS WITH DIABETES MELLITUS: ON THE WAY TO MUNICH-2008 Abstract  similar documents
I. I. Dedov, A. A. Alexanrov
"... блокаторы 194 (40,9) 201 (42,5) 117 (38,2) 0,4975 Аспирин 247 (52,1) 224 (47,4) 153 (50,0) 0,3421 Ингибиторы ..."
 
Vol 12, No 2 (2016) CARDIORENAL INTERACTION IN DECOMPENSATED CHRONIC HEART FAILURE Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, M. A. Efremovtseva
"... зависимости от СКФ. 4,8% 27,2% 26,4% 15,2% 1 2 3а 3б 4 5 22,4% 4% Ration Pharmacother Cardiol 2016 ..."
 
Vol 9, No 3 (2013) STATINS AND RISK OF INFECTIOUS DISEASES Abstract  similar documents
O. M. Drapkina, R. N. Shepel'
"... дней с момента госпитализации и 16,8% против 22,4% спустя 90 дней с момента госпитали- зации. При этом ..."
 
Vol 9, No 4 (2013) URAPIDIL: MODERN MEDICINE FOR THE TREATMENT OF HYPERTENSIVE CRISES Abstract  similar documents
A. V. Melekhov, Yu. I. Ostrovskaya
"... (49-71) НЗ Мужчин, n (%) 32 (48,4) 10 (50) НЗ Исходное САД, мм рт.ст. 212,5 (203-224) 204 (196-216) p ..."
 
Vol 10, No 5 (2014) DIABETIC CARDIOMYOPATHY. RESISTIN: A CONTROL OF A MYOCARDIAL HYPERTROPHY Abstract  similar documents
An. A. Aleksandrov, O. A. Shatskaya, S. S. Kuharenko, M. N. Yadrihinskaya, E. N. Abdalkina, E. N. Drozdova, M. V. Shestakova
"... ,2 [54,6; 61,7] 50 [57,7; 60,5] Площадь ЛП, мм2 22,4 [20,0; 25,3] 24,1 [20,1; 27,2] КДР ЛЖ, мм 48 [46; 51 ..."
 
Vol 9, No 6 (2013) WHAT DETERMINES QUALITY OF THE SCIENTIFIC JOURNAL? Abstract  similar documents
A. A. Kubanova, A. E. Karamova
"... .368 13.228 4.069 1.105 3,46 20,70 5 Sexually Transmitted Diseases 71 224 542 5.996 1.473 471 2,99 26 ..."
 
Vol 9, No 2 (2013) CONTEMPORARY APPROACH TO THE CORRECTION OF COGNITIVE DISORDERS IN PATIENTS WITH VASCULAR COMORBIDITY Abstract  similar documents
S. A. Rumianceva, V. A. Stupin, V. V. Afanas'ev, E. V. Silina, S. P. Svishсheva, E. N. Kabaeva, L. A. Cukurova
"... action of vinpocetine. Acta Pharm. Hung 1996;66(5):213–224. 22. Santos M.S., Duarte A.I., Moreira P.I. et ..."
 
Vol 1, No 1 (2005) NITRATES IN ISCHEMIC HEART DISEASE TREATMENT, YESTERDAY AND TODAY Abstract  similar documents
S. N. Tereschenko, N. A. Djaiani, E. V. Iljina
"... . 224-229с. 6. Чернова Е.В., Кучинская Н.Г и др. Оценка антиангинальной и антиишемической эффективности ..."
 
Vol 3, No 1 (2007) CHRONIC HEART FAILURE AND IRON-DEFICIENT ANEMIA Abstract  similar documents
M. V. Melnik, A. M. Shilov, I. R. Kim, O. N. Retivykh, A. A. Saricheva
"... больных с ХСН. Журнал Сердечная Недо- статочность. 2003; 4(5): 224-227. 2. Беленков Ю.Н. Классификация ..."
 
Vol 3, No 2 (2007) IMMUNO-INFLAMATORY RESPONSE IN ISCHEMIC HEART DISEASE Abstract  similar documents
N. E. Zakirova, N. Kh. Khafizova, I. M. Karamova, A. N. Zakirova, R. G. Oganov
"... груп- пы. Тем не менее, уровень ИЛ-10 был на 22,4%мень- ше, чем у больных стенокардией IIФК (р<0 ..."
 
Vol 6, No 4 (2010) EFFICACY OF VARIOUS DRUG FORMS OF LYCOPENE IN PATIENTS WITH DYSLIPIDEMIA Abstract  similar documents
P. Ya. Dovgalevsky, V. A. Klochkov, N. E. Chalyk, O. M. Ansimova, I. Petyaev
"... груп- пе А составил 220,3±14 мг/дл, Хс ЛНП — 150,5±9 мг/дл и МДА — 2,24±0,2 нМ/мл. В группе В эти по ..."
 
Vol 6, No 2 (2010) EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES Abstract  similar documents
A. N. Meshkov
"... - вастатина и у 22,4% — в группе аторвастатина, отра- жая уменьшение риска на 16% в пользу аторвастати- на (p ..."
 
Vol 3, No 5 (2007) THROMBOLYTIC THERAPY OF ACUTE MYOCARDIAL INFARCTION Abstract  similar documents
D. P. Sementsov
"... 61 >75 лет (%) 10.5 11.8 13.0 13.6 12.5 Женщины (%) 25.2 22.4 23.4 27.4 23.1 Частота ВМК ..."
 
Vol 3, No 5 (2007) RENAL HEMODYNAMICS AND GLOMERULAR FILTRATION RATE IN MEN AND WOMEN WITH ARTERIAL HYPERTENSION AT THE AGE OF 40-60 YEARS Abstract  similar documents
I. G. Fomina, A. E. Bragina, N. E. Gaydamakina, J. N. Salimzhanova
"... .ст. 178,0±22,4 176,0±22,3 0,67 ДАД (на момент госпи- тализации), мм рт.ст. 103,3±12,2 99,6±11,9 0 ..."
 
Vol 6, No 6 (2010) ACHIEVEMENT OF TARGET BLOOD PRESSURE LEVEL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 2-3 DEGREE WITH FIXED COMBINATION OF ENALAPRIL OR LOSARTAN WITH HYDROCHLOROTHIAZIDE Abstract  similar documents
A. A. Kudryavtsev, A. S. Ryazanov, N. N. Eremenko, S. A. Kireev
"... ,4±4,1 Умеренная ГЛЖ (150 г<ММЛЖ<200 г), % 25,3% 24,7% Выраженная ГЛЖ (ММЛЖ>200 г), % 22,4% 24,2% СД ..."
 
Vol 8, No 6 (2012) THE EFFECT OF MAGNESIUM DRUGS ON THE PHYSICAL PERFORMANCE OF YOUNG PEOPLE WITH MITRAL VALVE PROLAPSE: RESULTS OF NONCOMPARATIVE STUDY Abstract  similar documents
K. M. Dzeranova, A. G. Avtandilov, N. V. Vertkina
"... ,06±0,05* ИРС, % 46,40±2,17 66,80±2,02*** ХРС, % 78,50±2,24 84,50±1,15** ОВР, Вт 897,3±40,8 1036,3±31 ..."
 
1 - 100 of 176 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)